11 Things Doctors Are Still Getting Wrong About Menopause in 2025 — and How to Recognize Outdated Advice
The number of women who have told me their doctor said 'you're too young for perimenopause' — while they were standing there in a soaking-wet shirt at 3am — is genuinely staggering. The frustration is not just about the wrong answer. It is about the years of symptoms that went unnamed and untreated because someone did not keep up with the literature. That delay has a cost, and women deserve better.
Learn more about Rose →Dismissing perimenopause in women under 50
Perimenopause can begin in the early-to-mid 40s — and in some cases the late 30s — as progesterone begins declining years before estrogen follows. Waiting for periods to stop or for a woman to hit a specific birthday before taking symptoms seriously is not evidence-based practice; it is ageism dressed as medicine. Irregular cycles, sleep disruption, mood changes, and vasomotor symptoms in a woman over 38 deserve a perimenopause conversation, not a referral to a psychiatrist.
Using FSH as the only diagnostic test — and getting it wrong
A single FSH reading is an unreliable diagnostic tool during perimenopause because hormone levels fluctuate dramatically from week to week and even day to day. A normal FSH result does not rule out perimenopause, yet women are routinely told their bloodwork is 'fine' and sent home without further discussion. The Menopause Society and NICE both state clearly that perimenopause in women over 45 is a clinical diagnosis based on symptoms, not a lab result.
Still citing the 2002 WHI study as a reason to avoid HRT in healthy women
The Women's Health Initiative study — which produced the headlines that scared a generation of women and doctors away from hormone therapy — used older synthetic progestins and conjugated equine estrogens in women whose average age was 63, many of whom had pre-existing cardiovascular risk. Re-analyses and subsequent research, including the landmark 2017 and 2022 reappraisals, consistently show that for healthy women under 60 who are within 10 years of menopause onset, the benefit-to-risk ratio of HRT is favorable. Applying findings from a very different population to a healthy 48-year-old is not cautious medicine — it is outdated medicine.
Treating hot flushes as the only symptom worth addressing
Hot flushes and night sweats are the symptoms most doctors are trained to associate with menopause, but they represent a fraction of the hormonal transition's impact. Joint pain, cognitive changes, anxiety, palpitations, urinary symptoms, and changes in skin and libido are all well-documented effects of declining estrogen and progesterone — yet they are frequently attributed to aging, stress, or depression instead. A clinician who only asks about vasomotor symptoms is not conducting a complete menopause assessment.
Prescribing antidepressants as a first-line response to perimenopausal mood changes
Low mood, irritability, and anxiety that emerge during perimenopause in a woman with no prior psychiatric history are most likely driven by hormonal fluctuation — particularly the loss of progesterone's calming, GABAergic effects and the mood-stabilizing role of estrogen. Offering an SSRI without first discussing hormonal causes is not wrong in every case, but doing so without a menopause conversation at all is a significant oversight. Research published in JAMA Psychiatry and elsewhere confirms that estrogen therapy can be more effective than antidepressants for mood symptoms in perimenopausal women who do not have a primary depressive disorder.
Telling women that brain fog is just stress or poor sleep
Cognitive symptoms during perimenopause — word-finding difficulties, poor working memory, concentration problems — are neurologically real and have been documented in studies including the SWAN cognitive aging cohort. Estrogen plays a direct role in synaptic function, neuroinflammation, and brain glucose metabolism, and its fluctuation disrupts cognitive performance in measurable ways. Attributing these symptoms entirely to lifestyle factors without acknowledging the hormonal component leaves women frightened, misinformed, and without an effective path to relief.
Refusing to prescribe local vaginal estrogen due to breast cancer history concerns
Vaginal estrogen — delivered directly to local tissue at extremely low systemic doses — is not the same as systemic HRT, and the evidence does not support treating it as equivalent in terms of breast cancer risk. Major oncology bodies including ASCO have updated guidance stating that vaginal estrogen is generally acceptable even in many women with a history of hormone-sensitive breast cancer, particularly where quality of life is significantly impaired. Women are still being denied this treatment based on blanket policies rather than individualized, evidence-based assessment.
Not mentioning genitourinary syndrome of menopause (GSM) unless a woman raises it
Genitourinary syndrome of menopause — which includes vaginal dryness, thinning, urinary urgency, recurrent UTIs, and pain during sex — affects more than half of postmenopausal women, yet the majority report that their doctor never brought it up. Unlike vasomotor symptoms, GSM does not resolve on its own and typically worsens over time without treatment. Waiting for a patient to feel comfortable enough to mention painful sex is not good clinical practice; proactively asking is.
Applying arbitrary age cut-offs to stop or withhold HRT
Some clinicians still operate under the assumption that HRT should be stopped at age 60 or after five years of use — a guideline that has not been supported by current evidence for some time. The Menopause Society and the British Menopause Society both state that there is no blanket age at which HRT must be discontinued, and that duration decisions should be individualized based on a woman's symptoms, bone and cardiovascular health, and personal preferences. Automatically withdrawing treatment from a healthy, symptomatic woman because she reached a round number is not evidence-based care.
Treating all hormone therapies as interchangeable
Oral estrogen, transdermal estrogen, synthetic progestins, and micronized progesterone are not equivalent in their risk profiles, and treating them as such produces both unnecessarily cautious prescribing and genuinely risky oversight. Transdermal estradiol, for example, does not carry the elevated VTE risk associated with oral estrogen because it bypasses first-pass liver metabolism — a clinically meaningful difference. Micronized progesterone (body-identical) has a more favorable profile for sleep, mood, and likely breast cancer risk compared to older synthetic progestins, and women deserve to know those distinctions exist.
Assuming menopause care ends once periods stop
The postmenopausal years carry significant and ongoing health considerations — accelerating bone density loss, rising cardiovascular risk, metabolic changes, and continued GSM progression — none of which resolve simply because the perimenopause transition is complete. A 'you've gone through it now' attitude from clinicians leaves women without the monitoring, conversation, and potential treatment they need for long-term wellbeing. Menopause is not a finish line; it is a physiological shift that warrants continued, proactive healthcare.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.